奥希替尼联合司美替尼治疗EGFR突变伴BRAF改变的晚期NSCLC
ORCHARD平台II期研究评估奥希替尼联合MEK抑制剂司美替尼在EGFR突变晚期NSCLC一线奥希替尼进展后伴BRAF改变患者的疗效与安全性。16例患者接受治疗,客观缓解率仅7%,中位无进展生存期3.4个月,中位总生存期14.0个月,≥3级不良事件发生率69%。结论认为该联合方案应答极低,风险获益比不支持进一步评估。
要点
- 奥希替尼联合司美替尼在BRAF改变患者中ORR仅7%,仅1例部分缓解。
- 中位PFS 3.4个月,中位OS 14.0个月,≥3级不良事件69%。
- 风险获益比不支持该联合方案进一步评估。
核心结论
- 奥希替尼联合司美替尼在EGFR突变晚期NSCLC一线奥希替尼进展后伴BRAF改变患者中应答极低,风险获益比不支持进一步评估。
研究设计与样本
- ORCHARD(NCT03944772)为II期生物标志物匹配平台研究,本模块评估奥希替尼联合司美替尼在BRAF改变患者中的疗效与安全性。
- 患者接受奥希替尼80 mg每日一次联合司美替尼75 mg每日两次,直至疾病进展或不可耐受毒性。
- 共16例伴BRAF融合或BRAF V600E突变的患者接受治疗。
- 主要终点为研究者按RECIST 1.1评估的客观缓解率,次要终点包括无进展生存期、总生存期和安全性。
主要发现
- 客观缓解率为7%(80%CI <1-25),1例患者达部分缓解。
- 中位无进展生存期为3.4个月(95%CI 1.3-5.4),中位总生存期为14.0个月(95%CI 6.2-不可计算)。
- 安全性特征与两种药物已知特征一致,未发现新的安全信号。
临床怎么用
- 对于一线奥希替尼进展后伴BRAF改变的EGFR突变晚期NSCLC患者,不推荐奥希替尼联合司美替尼方案。
局限性
- 样本量小(16例),结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ORCHARD (NCT03944772) was a phase II, biomarker-matched, platform study designed to characterise resistance mechanisms and evaluate novel drug combinations in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) following disease progression on first-line osimertinib. We report final results of the module assessing the efficacy and safety of osimertinib plus selumetinib (a MEK inhibitor) in patients with BRAF alterations. METHODS: Patients with BRAF fusions or BRAF V600E mutations received osimertinib 80 mg once daily plus selumetinib 75 mg twice daily until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and safety. RESULTS: Overall, 16 patients received osimertinib plus selumetinib. At data cut-off, (25 November 2024) all patients had discontinued study treatment. The ORR was 7 % (80 % confidence interval [CI], < 1-25); one patient had a partial response. Median PFS was 3.4 months (95 % CI, 1.3-5.4) and median OS was 14.0 months (95 % CI, 6.2-not calculable). Eleven patients (69 %) had grade ≥ 3 adverse events, most commonly diarrhoea (19 %). CONCLUSION: Osimertinib plus selumetinib demonstrated minimal response in patients with EGFR-mutated advanced NSCLC with BRAF alterations following disease progression on first-line osimertinib. The safety profile of the combination was consistent with the known profiles of the two individual drugs; no new safety signals were identified. Overall, the risk-benefit profile suggests further evaluation of this combination is not warranted.
引用
- Piotrowska Z, Goldberg SB, Goldman JW, et al. Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. Eur J Cancer. 2026. PMID: 42202477. doi:10.1016/j.ejca.2026.116807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。